SAN CARLOS, CA, United States
SAN CARLOS, CA, United States

Time filter

Source Type

Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 223.52K | Year: 2014

Not Available


Patent
Cellerant Therapeutics, Inc. | Date: 2014-09-09

The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.


Grant
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase I | Award Amount: 200.79K | Year: 2013

DESCRIPTION (provided by applicant): State of the art techniques result in 10-year solid organ graft loss of up to 80% in cardiopulmonary organ transplantation, and re-transplantation is often not possible. Establishment of donor-specific immunological tolerance (DSIT), a condition in which a recipient accepts a transplant without immunosuppression, while retaining the ability to fight infections, would reduce graft loss. The only identified method of inducing robust tolerance involves Hematopoietic Cell Transplantation (HCT), usually in the form of bone marrow transplantation (BMT). Though long recognized experimentally as a means of inducing DSIT, clinical translation has been limited due to the associated complications. A major problem has been the treatment necessary to prepare a recipient for a blood cell transplant. White blood cell counts fall precipitously, resulting in neutropenia and increased susceptibility to infections To reduce infections associated with neutropenia in HCT recipients, unrelatedmyeloid progenitors (MP) can be injected together with the HCT. This therapy is effective in the laboratory setting in reducing deaths caused by bacterial and fungal infections, and several trials testing a clinical MP product developed by Cellerant Therapeutics (CLT-008) MP in humans are ongoing. We have discovered that injection of MP under these conditions results in MP-specific tolerance, even though there may be only very low-level MP engraftment after the first month. Important, MP from B10;B6-Rag2-/-Il2rg- /- mice, which are incapable of producing functional B, T or NK cells, induce tolerance and clearly show that organ graft-matched lymphoid cells are not essential under these conditions. Uniquely, MP cells induce antigen-specific tolerance in our experimental model system, are clinically available, and have been associated with minimal to no side effects in current clinical trials. MP constitute an ideal and innovative approach in tolerance induction protocols, preferred over efforts aimed at achieving high level donor chimerism. The proposed research in phase I will focus on (Aim 1) testing whether MP can prevent specific lung transplant rejection symptoms, important because lung transplants may be a good patient population for initial trials and(Aim 2) on testing the degree of mismatch allowed between MP and organ graft, as this will affect the production of clinical grade MP for clinical tolerance trils. The design of these trials using a Cellerant produced clinical MP product would be the nextstage following this STTR project. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The proposal aims to develop methods that can be used to improve the long-term outcome of clinical organ transplantations. State of the art technology results in upto 80% organ graft loss over ten years mostly due to rejection, and re-transplantation is often not possible. The academic partner has developed preclinical tolerance models and has shown that myeloid cells can induce specific tolerance. The small businesspartner is currently studying an innovative product (CTL-008, human Myeloid Progenitor Cells) in clinical trials for the prevention of infections. Together we are aiming to test if a commercial Myeloid Progenitor Cell product for the induction of tolerance in solid organ transplantation is feasible and to transfer this technology to the small business partner for further clinical development and application such that it can improve the long-term outcome for patients undergoing transplantation for end-stage organ failure.


Patent
Cellerant Therapeutics, Inc. | Date: 2014-08-12

Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.


Patent
Cellerant Therapeutics, Inc. | Date: 2013-03-11

Provided herein are antibodies specific for CLL-1.


Patent
Cellerant Therapeutics, Inc. | Date: 2013-08-14

The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.


Patent
Cellerant Therapeutics, Inc. | Date: 2016-02-19

This disclosure provides novel isoquinolidinobenzodiazepines. These compounds can also be incorporated into antibody-drug conjugates.


Patent
Cellerant Therapeutics, Inc. | Date: 2015-09-14

Provided herein are antibodies specific for CLL-1.


Patent
Cellerant Therapeutics, Inc. | Date: 2013-12-20

Methods and compositions for binding to the membrane-bound form of IL1 RAP. In some embodiments, the invention provides an isolated antibody that binds the membrane bound fom1 of human IL1 RAP. In some cases, the isolated antibody that binds the membrane-bound form of human IL1 RAP does not bind, or does not substantially bind, the soluble form of human IL1 RAP. For example, in some cases, the isolated antibody that binds the membrane-bound form of human IL1RAP does not bind, or does not substantially bind the soluble form of human IL1RAP that is found in normal human serum. In some cases, the soluble form of human IL1 RAP comprises the sequence GNRCGQ.


The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.

Loading Cellerant Therapeutics, Inc. collaborators
Loading Cellerant Therapeutics, Inc. collaborators